MedTech Terms
    The authoritative reference
    All terms
    Clinical & TrialsQuality SystemClinical EvidenceRBM

    Risk-Based Monitoring

    Monitoring strategy that targets oversight resources to the highest-risk sites, processes, and data based on a documented risk assessment, replacing 100% source data verification.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed June 20, 2026

    Definition

    Risk-Based Monitoring (RBM) is a clinical trial oversight approach that uses a documented risk assessment to direct monitoring resources to the trial elements (sites, processes, data points) most critical to subject safety and data integrity. Rather than performing 100% source data verification (SDV) at every site, sponsors combine centralized statistical monitoring (off-site analytics on EDC data), targeted on-site monitoring focused on critical data and processes, and remote source data review where feasible. The broader practice, Risk-Based Quality Management (RBQM), extends this approach to all quality oversight activities.
    What the regulation says
    ICH E6(R2) §5.18.3 and E6(R3) §3.10 establish RBM expectations. FDA's 'Oversight of Clinical Investigations - A Risk-Based Approach to Monitoring' guidance (2013, refreshed 2023) is the primary U.S. reference.

    What this means in practice

    RBM became the default expectation under ICH E6(R2) addendum (2016) and is reinforced in E6(R3) (2023). For device IDE studies, sponsors implementing RBM must produce a documented risk assessment, defined Key Risk Indicators (KRIs) and Quality Tolerance Limits (QTLs), trigger-based monitoring procedures, and centralized monitoring analytics. FDA bioresearch monitoring inspections increasingly evaluate RBM implementation depth.
    Common pitfalls
    • •Declaring RBM without a documented risk assessment, the assessment is the foundation; without it, RBM is just reduced SDV.
    • •Setting KRIs/QTLs without thresholds for action, KRIs that no one acts on add cost without benefit.
    • •Cutting on-site visits to zero, RBM redistributes monitoring, it doesn't eliminate it.

    Primary references

    3 sources
    Link health: 2 verified 1 bot-blocked· last checked 2026-06-20
    FDA·1ICH·1NIH·1
    1. 1
      FDA Oversight of Clinical Investigations Guidance
      Bot-blocked
      FDAfda.gov
    2. 2
      ICH E6(R3) Good Clinical Practice
      Verified
      ICHich.org
    3. 3
      ClinicalTrials.gov
      Verified
      NIHclinicaltrials.gov

    Inline markers like [1] jump to the matching reference above.